FREE delivery to all EXCLUSIVE BOOKS stores nationwide. FREE delivery to your door on all orders over R450. Excludes all international deliveries.

Health Care Policy and Regulation

Thomas A. Abbott III
    Product form
      FORMAT: Paperback / softback

      R 3,303.93 Price and availability exclusive to website

      YOU COULD EARN 3,303.93 FUTURE RETAIL DISCOUNTS.
      ESTIMATED DELIVERY: Approx. 10 - 15 Business Days
      BUY NOW PAY LATER
      From R 550.65 per month!
      3x monthly payments of R 1,101.31 with
      4x fortnightly payments of R 825.98 with
      5 care reforms. Part II: Price Regulation The second partofthis volume examines the role ofprice regulation in controlling health care costs. It contains three chapters. In chapter seven, I examine the alternatives for regulating pharmaceutical prices. In chapter eight, Jack Hadley examines the impactofvarious forms ofhospital price regulation; while in chapter nine,MarkPaulyexaminestheroleofpriceregulation incontrollingphysician fees. Chapter seven focuses on the issue of regulating pharmaceutical prices. There are two key issues examined in this paper. First, is there a clear need for price regulation, and second, can price regulation work in this industry? In response to the first question, I come to the conclusion that the proponents ofprice regulation have not really proven their case. Although the financial returns in the pharmaceu­ tical industry have been slightly higher than expected during the 1970s and 1980s, there is not overwhelming evidence of"price gouging" or excessive profits on the part of the industry. In response to the second question, the answer is clearly no. The traditional approaches to price regulation will not have the intended affect of eliminating excess profits from the industry while maintaining the incentives for research and development. First, rate-of-return regulation, the most natural approach, would result in many adverse incentives-includingexcessive investment in research and developmentinorderto inflatetheratebaseused tocalculatedtheallowablereturns.
      Format: Paperback / softback CONTRIBUTORS: Thomas A. Abbott III EAN: 9781461359326 COUNTRY: United States PAGES: WEIGHT: 408 g HEIGHT: 0 cm
      PUBLISHED BY: Springer-Verlag New York Inc. DATE PUBLISHED: 2012-09-27 CITY: GENRE: BUSINESS & ECONOMICS / Industrial Management, MEDICAL / Public Health, POLITICAL SCIENCE / Public Policy / Economic Policy WIDTH: 0 cm SPINE:

      Book Themes:

      Economics of industrial organization, Political economy, Public health and preventive medicine

      Customer Reviews

      Be the first to write a review
      0%
      (0)
      0%
      (0)
      0%
      (0)
      0%
      (0)
      0%
      (0)
      5 care reforms. Part II: Price Regulation The second partofthis volume examines the role ofprice regulation in controlling health care costs. It contains three chapters. In chapter seven, I examine the alternatives for regulating pharmaceutical prices. In chapter eight, Jack Hadley examines the impactofvarious forms ofhospital price regulation; while in chapter nine,MarkPaulyexaminestheroleofpriceregulation incontrollingphysician fees. Chapter seven focuses on the issue of regulating pharmaceutical prices. There are two key issues examined in this paper. First, is there a clear need for price regulation, and second, can price regulation work in this industry? In response to the first question, I come to the conclusion that the proponents ofprice regulation have not really proven their case. Although the financial returns in the pharmaceu­ tical industry have been slightly higher than expected during the 1970s and 1980s, there is not overwhelming evidence of"price gouging" or excessive profits on the part of the industry. In response to the second question, the answer is clearly no. The traditional approaches to price regulation will not have the intended affect of eliminating excess profits from the industry while maintaining the incentives for research and development. First, rate-of-return regulation, the most natural approach, would result in many adverse incentives-includingexcessive investment in research and developmentinorderto inflatetheratebaseused tocalculatedtheallowablereturns.
      Format: Paperback / softback CONTRIBUTORS: Thomas A. Abbott III EAN: 9781461359326 COUNTRY: United States PAGES: WEIGHT: 408 g HEIGHT: 0 cm
      PUBLISHED BY: Springer-Verlag New York Inc. DATE PUBLISHED: 2012-09-27 CITY: GENRE: BUSINESS & ECONOMICS / Industrial Management, MEDICAL / Public Health, POLITICAL SCIENCE / Public Policy / Economic Policy WIDTH: 0 cm SPINE:

      Book Themes:

      Economics of industrial organization, Political economy, Public health and preventive medicine

      Customer Reviews

      Be the first to write a review
      0%
      (0)
      0%
      (0)
      0%
      (0)
      0%
      (0)
      0%
      (0)

      Recently viewed products

      Login

      Forgot your password?

      Don't have an account yet?
      Create account